Case report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment
Zhi-Jie Wang, Ying-Fang Nie, Shi-Bing Liang, Jing Zhou, Shu-Lan Hao, Li-Kun Liu · 2025
Read Case report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment by Zhi-Jie Wang, Ying-Fang Nie, Shi-Bing Liang, Jing Zhou, Shu-Lan Hao, Li-Kun Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11769789.txt.
Description
Zhi-Jie Wang and co-authors report a rare case of dangerously low blood sodium appearing late during cancer treatment. Their patient, a sixty-eight-year-old woman with recurrent cancer of the upper urinary tract, had surgery, then relapsed a year later with mildly reduced kidney function. Eight days after her first round of gemcitabine, cisplatin, and the immunotherapy drug tislelizumab, her sodium crashed to life-threatening levels.
Suspecting cisplatin, the team split its dose across three days in the next round, and no severe drop followed; scans showed the tumour shrinking. Later, severe marrow suppression pushed her to tislelizumab alone, on which her tumour stayed stable. The authors suggest low-dose spread-out cisplatin may suit patients with borderline kidneys better than one full dose, while flagging that the other drugs might also lower sodium. More observation is needed, they note.
Catalog record
| CREATOR | Zhi-Jie Wang, Ying-Fang Nie, Shi-Bing Liang, Jing Zhou, Shu-Lan Hao, Li-Kun Liu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |